This Article Full Text Full Text (PDF) A correction has been published Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Bach, F. H. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Bach, F. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Islet Cell Transplantation

Bilirubin Can Induce Tolerance to Islet Allografts

Department of Surgery, Beth Israel Deaconess Medical Center (H.W., S.S.L., J.D., E.C., B.Y.C., F.H.B.) and Joslin Diabetes Center (V.T.), Harvard Medical School, Boston, Massachusetts 02215; and Department of Experimental Medicine and Biotechnology (C.D.), University of Milano-Bicocca, 20052 Monza-Milano, Italy

Address all correspondence and requests for reprints to: Hongjun Wang, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue, Boston, Massachusetts 02215. E-mail: hwang3{at}bidmc.harvard.edu.

Induction of heme oxygenase-1 (HO-1) expression in recipients of allogeneic islets can lead to long-term survival (>100 d) of those islets. We tested whether administration of bilirubin would substitute for the beneficial effects of HO-1 expression in islet transplantation. Administering bilirubin to the recipient (B6AF1) or incubating islets in a bilirubin-containing solution ex vivo led to long-term survival of allogeneic islets in a significant percentage of cases. In addition, administering bilirubin to only the donor frequently led to long-term survival of DBA/2 islets in B6AF1 recipients and significantly prolonged graft survival of BALB/c islets in C57BL/6 recipients. Donor treatment with bilirubin up-regulated mRNA expression of protective genes such as HO-1 and bcl-2 and suppressed proinflammatory and proapoptotic genes including monocyte chemoattractant protein-1 and caspase-3 and -8 in the islet grafts before transplantation. Furthermore, treatment of only the donor suppressed the expression of proinflammatory cytokines including TNF-, inducible nitric oxide synthase, monocyte chemoattractant protein-1, and other proapoptotic and proinflammatory genes normally seen in the islets after transplantation. Donor treatment also reduced the number of macrophages that infiltrated the islet grafts in the recipients. Preincubation of ßTC3 cells with bilirubin also protected the cells from lipid peroxidation. Our data suggests that the potent antioxidant and antiinflammatory actions of bilirubin may contribute to islet survival.

This article has been cited by other articles:

				Y. Liu, P. Li, J. Lu, W. Xiong, J. Oger, W. Tetzlaff, and M. Cynader Bilirubin Possesses Powerful Immunomodulatory Activity and Suppresses Experimental Autoimmune Encephalomyelitis J. Immunol., August 1, 2008; 181(3): 1887 - 1897. [Abstract] [Full Text] [PDF]

				N. G. Abraham and A. Kappas Pharmacological and Clinical Aspects of Heme Oxygenase Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127. [Abstract] [Full Text] [PDF]

				A. Goldberg, M. Parolini, B. Y. Chin, E. Czismadia, L. E. Otterbein, F. H. Bach, and H. Wang Toll-like receptor 4 suppression leads to islet allograft survival FASEB J, September 1, 2007; 21(11): 2840 - 2848. [Abstract] [Full Text] [PDF]

				C.-M. Hu, H.-H. Lin, M.-T. Chiang, P.-F. Chang, and L.-Y. Chau Systemic Expression of Heme Oxygenase-1 Ameliorates Type 1 Diabetes in NOD Mice Diabetes, May 1, 2007; 56(5): 1240 - 1247. [Abstract] [Full Text] [PDF]